Stimvia Announces Completion of Enrollment in Pilot Study for Parkinson's Diseases and Essential Tremor
Retrieved on:
Mercoledì, Novembre 8, 2023
Alzheimer's disease, Patient, Research, Delayed onset muscle soreness, ET, Essential tremor, PD, Science, Overactive bladder, University of Ostrava, Conditional sentence, Medical school, Deep brain stimulation, Quality of life, DSM-IV codes, Parkinson's disease, Walking, Safety, Doctor of Philosophy, Central nervous system, Pharmaceutical industry, MD
PRAGUE, Nov. 8, 2023 /PRNewswire/ -- Stimvia , a company specializing in the use of neuromodulation for the treatment of chronic diseases, successfully completed recruitment for a pilot study focused on the treatment of Parkinson's disease (PD) and essential tremor (ET).
Key Points:
- PRAGUE, Nov. 8, 2023 /PRNewswire/ -- Stimvia , a company specializing in the use of neuromodulation for the treatment of chronic diseases, successfully completed recruitment for a pilot study focused on the treatment of Parkinson's disease (PD) and essential tremor (ET).
- Patients will be using the URIS® device , which employs a new method called peroneal neuromodulation (eTNM®) for deep brain stimulation.
- The study assesses the impact on symptoms of patients with PD or ET disorders, as well as the influence of treatment on their quality of life.
- 24 patients, half with ET and half with PD, are part of the study.